CalciMedica

62 articles about CalciMedica

• CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy

  5/7/2020

  CalciMedica Inc., a clinical-stage biotechnology company targeting calcium release-activated calcium channels for the treatment of acute and severe inflammatory diseases, announced that the Independent Safety Review Committee recommended that its open-label Phase 2 study evaluating the safety, efficacy and pharmacokinetic profile of CM4620-IE in patients with severe COVID-19 pneumonia continue as planned.

• 

  Biopharma Update on the Novel Coronavirus: May 7

  5/7/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
• 

  Clinical Catch-Up: April 27-May 1

  5/4/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.

• CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy

  4/30/2020

  Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients

• 

  Clinical Catch-Up: April 13-17

  4/20/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: April 16

  4/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.

• FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND

  4/9/2020

  Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry Ford Hospital in Detroit is expected to begin a trial within the next week

• Henry Ford Hospital Physician Presents Results from the Initial Patient Study of CalciMedica's CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at ACEP Meeting

  10/30/2019

  Joseph Miller, MD, MS, a physician at the Henry Ford Health System in Detroit, MI, and a key Principal Investigator on CalciMedica's initial acute pancreatitis clinical study of its calcium release-activated calcium channel inhibitor CM4620-IE, presented on the study at the annual meeting of the American College of Emergency Physicians being held in Denver, CO from October 27-30.

• CalciMedica, Inc. to Present Study Population Profile from its Initial Patient Study of its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference

  3/20/2019

  Physicians from several study sites involved in CalciMedica's initial acute pancreatitis clinical study of its CRAC channel inhibitor CM4620 and CalciMedica, Inc., presented a poster at the 39th International Symposium on Intensive Care and Emergency Medicine being held in Brussels on March 19-22.

• CalciMedica Doses First Patients in Acute Pancreatitis Clinical Study

  8/2/2018

  CalciMedica announced that the first patients in a Phase 2a clinical study for acute pancreatitis have been dosed with its proprietary calcium release-activated calcium (CRAC) channel inhibitor CM4620.

• CalciMedica Names Two Senior Executives to its Board of Directors

  5/1/2018

  CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger, JD, MBA, a co-founder and Chief Business Officer of Escalier Biosciences.

• CalciMedica Receives Fast-Track Designation For CM4620, A Novel CRAC Channel Inhibitor To Treat Acute Pancreatitis

  5/25/2017

• CalciMedica Initiates Phase 1 Clinical Studies For CRAC Channel Inhibitor

  1/6/2017

• CalciMedica And University of Liverpool Announce Publication On CRAC Channel Inhibitors For Acute Pancreatitis

  7/27/2015

• CalciMedica Appoints Michael Dunn as SVP, Corporate Development

  8/20/2013

• CalciMedica Moves Psoriasis Drug Into Clinic, Pockets $6M

  2/18/2011

• CalciMedica Appoints Steven L. Schoenfeld, MD, as Vice President, Clinical Development

  6/23/2010

• CalciMedica Achieves Milestone and Draws Down Second Tranche of $12 Million Series C Financing

  12/15/2009

• CalciMedica Appoints Evelyn Graham to its Board of Directors

  10/13/2009